人胃癌细胞系中P53抑癌基因变异的检测及其序列分析

Ｐ５３抑癌基因由于点突变,缺失或易位等方式而丧失活性是多种瘤发生发展的重要机理之一。本文应用聚合酶链式反应－－单链构锡多态性分析（ＰＣＲ－ＳＳＣＰ）方法,对四种人胃癌细胞系ＭＧＣ８０３,ＢＧＣ８２３,ＧＣ７９０１和ＰＡＭＣ－８２中Ｐ５３基因的第５、６、７、８四个外显子进行检测,结果发现,ＰＡＭＣ－８２的第５第第８外显子,ＧＣ７９０１的第６外显子存在突变,ＰＣＲ－直接测序证明,它们分别在１７４位、２     

PCR—SSCP检测肺癌细胞p53基因点突变

应用溴化乙锭（ＥＢ）染色的ＰＣＲ－ＳＳＣＰ技术对１０例非小细胞性肺癌组织标本ｐ５３基因外显子５￣８进行分析,其中１例在外显子５￣６;１例在外显子７;２例在外显子８发现异常电泳带。对１例经ＳＳＣＰ检测异常的ｐ５３基因进行核酸序列分析,发现第２８０位密码子ＡＣＡ,其编码的氨基酸由丝氨酸变成半胱氨酸。结果证实：非小细胞性肺癌与ｐ５３基因突变有关;ＥＢ法ＰＣＲ－ＳＳＣＰ技术是一种简便、可靠的点突变检测法。     

非同位素PCR－SSCP方法的初步临床应用

单链构象多态性检测法（ＰＣＲ－ＳＳＣＰ）是近年发展起来的一项检测人类基因组突变的新技术。然而,在该技术中需要使用放射性同位素标记的核苷酸或引物,从而限制了其广泛临床研究及诊断方面的应用。本文报告一种改进的ＰＣＲ－ＳＳＣＰ方法,该方法不用同位素标记引物,而直接在溴乙啶染色的聚丙烯酰胺凝胶上显示ＳＳＣＰ。用该方法对５５例平滑肌肉瘤ｐ５３基因第７外显子突变的检测表明,３８％的瘤组织ＤＮＡ存在异常的ＳＳＣＰ。其中１０例有ＨａｅⅢ和ＭｓｐＩ酶切位点的突变（１８％）,１９例有突变型ｐ５３蛋白的过度表达（９例同时有异常ＳＳＣＰ改变）。而ｐ５３质粒ＤＮＡ,平滑肌瘤及Ａｌｚｈｅｉｍｅｒ病患者基因组ＤＮＡ无ｐ５３基因第７外显子扩增片段的异常ＳＳＣＰ改变。同时,还使用该方法对临床诊断的２０例Ａｌｚｈｅｉｍｅｒ病患者和８例健康对照进行了β－淀粉样蛋白前体基因第１６和１７外显子的扩增及分析,均未发现有异常ＳＳＣＰ改变及ＥｃｏＲＩ,ＢｃｌＩ酶切位点的突变。本研究结果提示,该非同位素ＰＣＲ－ＳＳＣＰ方法可靠、敏感、简便、快速,具有潜在的推广价值。     

p16抑癌基因定点突变及其在大肠杆菌中的表达与纯化

为了研究错义突变对ｐ１６功能的影响,应用ＰＣＲ体外定点突变方法对ｐ１６ｃＤＮＡ进行体外定点突变,并将野生型和突变型ｐ１６ｃＤＮＡ克隆于ｐＧＥＸ－５Ｔ载体,在大肠杆菌中经ＩＰＴＧ诱导表达,Ｗｅｓｔｅｒｎ印迹鉴定确证表达．而后用谷胱甘肽－Ｓｅｐｈａｒｏｓｅ４Ｂ亲和层析纯化野生型和突变型ｐ１６融合蛋白．得到了第４８位密码子ＣＣＧ（Ｐｒｏ）→ＣＴＧ（Ｌｅｕ）突变的ｐ１６－Ｐ４８突变体,并在大肠杆菌中表达了４２ｋＤ的ＧＳＴ－ｐ１６和ＧＳＴ－ｐ１６Ｐ４８Ｌ融合蛋白．最后经纯化得到了野生和Ｐ４８Ｌ突变的ｐ１６融合蛋白     

BRCA1基因结构及其在乳腺癌中的表达

利用ＭＰＣＲ技术从乳腺组织分离到抑癌基因ＢＲＣＡ１的ｃＤＮＡ片段,将此９１４ｂｐ的片段克隆进质粒ｐＵＣ１１８,并经全序列测定证实。序列分析表明,ＢＲＣＡＩｃＤＮＡ编码的肽链ＮＮ２－末端有一锌指结构,抑癌基因ＢＲＣＡＩ的产物可能是ＤＮＡ结合蛋白,ｃＤＮＡ序列存在两个变异位点：一个是第４０９位的Ｃ→Ａ（Ａｓｐ→Ｇｌｕ）：另一个是第８７９位的Ａ→Ｔ（ＭＩａ同义突变）。以该片段为探针,检测６例乳腺癌组织中ＢＲＣＡＩｍＩＭＡ表达,一例表达明显下降,一例没检测到表达的ｍＩＭＡ产物,说明一些乳腺癌组织的ＢＲＣＡ１基因转录水平降低     

球形幽门螺杆菌分子生物学研究

为研究幽门螺杆菌（ＨＰ）球形变异本质,作者通过延期培养和采用亚抑菌浓度抗生素,使３株ＨＰ发生球形变异,对弯曲形和球形ＨＰ作了ＳＤＳ－ＰＡＧＥ、免疫印迹及４个毒力基因片段ＰＣＲ和ＰＣＲ－ＳＳＣＰ分析。ＳＤＳ－ＰＡＧＥ图谱显示球形ＨＰ分子量在７４×１０４以上的蛋白含量减少,免疫印迹显示球形ＨＰ１２５×１０４蛋白条带反应减弱,而抗生素诱变的球形ＨＰ分子量为１１×１０４和６３×１０４的蛋白条带反应增强。ＰＣＲ及ＰＣＲ－ＳＳＣＰ结果表明球形ＨＰ的ｈｐａＡ,ＶａｃＡ,ＣａｇＡ和ＵｒｅＡ４个毒力基因片段未发生缺失,但在ｈｐａＡ或ＶａｃＡ基因中存在点突变     

t-PA cDNA的克隆及其在毕赤酵母中的表达

应用ＰＣＲ方法,在ｔ－ＰＡ ｃＤＮＡ５＇端引入合适的限制酶位点和酵母分泌信号肽,与酵母表达载体ｐＰＩＣ９重组,构建表达质粒ｐＳＴＥ－Ｙ,利用ＬｉＣｌ转化法转化酵母菌ＹＳ１０８,在ＭＭ和ＭＤ平板上筛选表型,ＰＣＲ筛选ｔ－ＰＡ ｃＤＮＡ与酵母染色体整合而形成的阳性克隆,阳性克隆经甲醇诱导表达后,用ＳＤＳ－ＰＡＧＥ证明表达产物的分子量为６ｋＤａ左右,用酪蛋白板溶圈法测定ｔ－ＰＡ的活性。Ｍｕｔ＾ｓ表型菌表     

噬菌体展示的豆蔻酰转移酶抑制肽序列结构和功能研究

对一个具有很强的抑制豆蔻酰转移酶活性的抑制肽噬菌体所展示的随机区１５肽序列ＴＷＰＶＶＨＧＡＣＲＡＨＧＨＣ进行关键氨基酸残基的单点,双点和缺失等一系列突变研究,以确定其功能区段。结果显示;Ｗ２Ａ,Ｈ６Ｎ和Ｈ６Ｒ突变抑制活性明显下降,Ｐ３Ａ,Ｖ４Ｖ５→Ｖ４Ａ５双点突变对活性也有一定的影响,而Ｖ４Ｖ５→Ｗ４Ｗ５,Ｈ１２Ｎ,Ｈ１４Ｎ,Ｃ９Ｓ,Ｃ１５Ｓ,ΔＣ１５,ΔＨ１４Ｃ１５和Δ９－Ｃ１５等突变对则基本上     

PCR—单链构象多态性分析对p53基因点突变检测的研究进展

单链构象多态性（ＳＳＣＰ）对分析基因的突变是一种有效的手段,并具有其独特的优点。ＰＣＲ与ＳＳＣＰ结合后检测灵敏度更高,而在许多类型的肿瘤都存在有ｐ５３抑癌基因的突变,章综述了ＰＣＲ－ＳＳＣＰ分析技术检测ｐ５３基因突变的进展。     

11例重度内源性高甘油三酯血症患者脂蛋白脂酶基因的序列分析

对成都地区１１例重度内源性高甘油三酯血症（空腹１２～１４小时血浆ＴＧ＞７．６８ｍｍｏｌ／Ｌ）患者脂蛋白脂酶基因外显子１～９的序列进行了分析。结果发现,１１例患者中有４例其ＬＰＬ基因在外显子６,８及９具有３种杂合子变异。其中一种为Ｔｈｒ３６１－Ｔｈｒ（外显子８,Ｃ１３３８→Ａ）突变,为无义突变,尚未见报道,在７４例血脂正常的中国人中的发生频率为１１．４％。另外２种变异Ａｌａ２６１－Ｔｈｒ（外显子６,Ｇ１０３７→Ａ）及Ｓｅｒ４４７－Ｔｅｒ（外显子９,Ｃ１５９５→Ｇ）在７４例血脂正常中国人的频率分别为０％及１０．７％。未发现脂蛋白脂酶催化活性中心Ａｓｐ１５６－Ｈｉｓ２４１－Ｓｅｒ１３２（外显子４及５）的突变。     

绿茶对人胃癌细胞株中p21,p53蛋白表达的影响

应用免疫细胞化学方法检测ＳＧＣ—７９０１胃癌细胞株中ｐ２１、ｐ５３蛋白的表达,以探讨绿茶的抗癌作用机理。结果表明：绿茶提取物明显抑制ＳＧＣ—７９０１胃癌细胞株中ｐ２１ｒａｓ、ｐ５３蛋白的表达,并有剂量效应。提示绿茶对ｐ２１、ｐ５３基因突变可能有修复作用     

MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer

Background

MicroRNAs (miRNAs) are important regulators that play key roles in tumorigenesis and tumor progression. A previous report has shown that let-7 family members can act as tumor suppressors in many cancers. Through miRNA array, we found that let-7f was downregulated in the highly metastatic potential gastric cancer cell lines GC9811-P and SGC7901-M, when compared with their parental cell lines, GC9811 and SGC7901-NM; however, the mechanism was not clear. In this study, we investigate whether let-7f acts as a tumor suppressor to inhibit invasion and metastasis in gastric cancers.

Methodology/Principal

Real-time PCR showed decreased levels of let-7f expression in metastatic gastric cancer tissues and cell lines that are potentially highly metastatic. Cell invasion and migration were significantly impaired in GC9811-P and SGC7901-M cell lines after transfection with let-7f-mimics. Nude mice with xenograft models of gastric cancer confirmed that let-7f could inhibit gastric cancer metastasis in vivo after transfection by the lentivirus pGCsil-GFP- let-7f. Luciferase reporter assays demonstrated that let-7f directly binds to the 3′UTR of MYH9, which codes for myosin IIA, and real-time PCR and Western blotting further indicated that let-7f downregulated the expression of myosin IIA at the mRNA and protein levels.

Conclusions/Significance

Our study demonstrated that overexpression of let-7f in gastric cancer could inhibit invasion and migration of gastric cancer cells through directly targeting the tumor metastasis-associated gene MYH9. These data suggest that let-7f may be a novel therapeutic candidate for gastric cancer, given its ability to reduce cell invasion and metastasis.     

p53突变蛋白在胃癌组织中的表达及免疫电镜观察

作者应用抗ｐ５３单克隆抗体Ｐａｂ１８０１（Ａｂ２美国癌基因公司产品）对３８例手术切除的胃癌组织及癌旁胃粘膜的冰冻切片标本进行ｐ５３突变蛋白表达的检测,并进一步用胶体全免疫电镜技术对ｐ５３突变蛋白的分布特征进行观察。结果：３８例胃癌组织中,２４例有ｐ５３突变蛋白高表达,阳性率６３．２％。在对应的癌旁胃粘膜中１０例为ｐ５３的弱表达,正常组织无表达。伴有淋巴结转移的２３例胃癌标本中,１８例ｐ５３高表达（７８．３％）。免疫电镜结果表现,ｐ５３蛋白主要分布于核内染色质中,胞浆中有散在的阳性区,但以核膜周边为主,紧靠核膜。本研究结果提承胃癌的发生及其肿瘤的生物学行为与抑癌基因ｐ５３的突变密切相关,ｐ５３突变蛋白可能是通过对ＤＮＡ复制的影响而参与肿瘤的形成。     

The detection of mutations induced in vitro in the human p53 gene by hydrogen peroxide with the restriction site mutation (RSM) assay.

We have analysed five mutation hotspots within the p53 gene (codons 175, 213, 248, 249, and 282) for mutations induced by hydrogen peroxide (H(2)O(2)), employing the restriction site mutation (RSM) assay. In addition, four other restriction sites covering non-hotspot codons of exons 5-9 of the p53 gene (codons 126, 153/54, 189 and the 3' splice site of exon 9) were analysed by the RSM assay for H(2)O(2)-induced mutations. Two cell types were concurrently analysed in this study, i.e. primary fibroblast cells and a gastric cancer cell line. Using the RSM assay, H(2)O(2)-induced mutations were only detected in exon 7 of the p53 gene. This was true for both cell types. These mutations were mainly induced in the Msp I restriction site (codon 247/248) and were predominantly GC to AT transitions (71%). Hence these GC to AT mutations were presumably due to H(2)O(2) exposure, possibly implicating the 5OHdC adduct, which is known to induce C to T mutations upon misreplication. Importantly, this study demonstrates that the RSM methodology is capable of detecting rare oxidative mutations within the hotspot codons of the p53 tumour suppressor gene. Hence, this methodology may allow the detection of early p53 mutations in pre-malignant tissues.     

Association of the p53 codon 72 polymorphism to gastric cancer risk in a hight risk population of Costa Rica

Gastric cancer is the second most common cancer associated death cause worldwide. Several factors have been associated with higher risk to develop gastric cancer, among them genetic predisposition. The p53 gene has a polymorphism located at codon 72. which has been associated with higher risk of several types of cancer, including gastric cancer. The aim of this study was to determine the association of p53, codon 72 polymorphism. with the risk of gastric cancer and pre-malignant lesions in a high-risk population from Costa Rica. The genotyping was carried out by PCR-RFLP in 58 gastric cancer patients, 99 controls and 41 individuals classified as group I or II. according to the Japanese histological classification. No association was found for p53. codon 72 polymorphism with neither the risk of gastric cancer nor the risk of less severe gastric lesions in the studied population. Based on this study and taking into account other studies carried out with p53, codon 72 polymorphism. the role of this polymorphismn in the development of gastric cancer remains unclear. De novo mutations on p53 gene produced during neoplasic development of this disease might play a greater role than germinal polymorphisms of the gene. Other polymorphic genes have been associated with higher risk to develop gastric cancer.     

Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis

High expression of PRL-3, a protein tyrosine phosphatase, is proved to be associated with lymph node metastasis in gastric carcinoma from previous studies. In this paper, we examined the relationship between PRL-3 expression and peritoneal metastasis in gastric carcinoma. We applied the artificial miRNA (pCMV-PRL3miRNA), which is based on the murine miR-155 sequence, to efficiently silence the target gene expression of PRL-3 in SGC7901 gastric cancer cells at both mRNA and protein levels. Then we observed that, in vitro, pCMV-PRL3miRNA significantly depressed the SGC7901 cell invasion and migration independent of cellular proliferation. In vivo, PRL-3 knockdown effectively suppressed the growth of peritoneal metastases and improved the prognosis in nude mice. Therefore, we concluded that artificial miRNA can depress the expression of PRL-3, and that PRL-3 might be a potential therapeutic target for gastric cancer peritoneal metastasis.     

胃癌细胞中Ras基因的表达、突变分析及新剪接型Kras△E2的发现

目的：传统Ras家族由Kras,Hras和Nras基因组成,这类基因的点突变经常在人类肿瘤中发现,突变热点位于12,13,61位密码子。ERas基因是2003年在鼠胚胎干（ES）细胞中发现的,其cDNA编码的蛋白与Kras,Hras和Nras分别有46％,43％和47％的相似性,故属于新的Ras家族成员,近几年发现ERas基因的表达与胃癌密切相关,而传统Ras基因在胃癌细胞中的表达及突变情况系统报道较少,本文旨在研究传统Ras基因Kras,Hras,Nras及其家族新成员ERas基因在胃癌细胞中的表达和突变情况。方法：选用7株不同来源不同分化程度的胃癌细胞系,利用RT—PCR及real-timePCR检测Ras基因在这些胃癌细胞系中的表达,并通过测序对传统Ras基因突变热点12,13,61位密码子及ERas基因全长进行突变分析。结果：QRas基因在这些胃癌细胞系中均有不同程度的表达,其中Hras和Nms基因在各株细胞中表达水平均一,而Kras和ERas基因则呈差异性表达;②在这些胃癌细胞中传统Ras基因突变热点12,13,61位密码子不存在突变,ERas基因全长亦未检测到突变．③发现Kras基因一新的剪接型,特点为第一、三外显子直接拼接,缺失第二外显子,命名为Kras△E2。结论：与在其他肿瘤中不同,传统Ras基因在胃癌细胞中不存在突变热点,家族新成员ERas基因全长亦无突变,在国际上首次报道新剪接型Kras△E2,从而得出创新性结论：Ras基因家族在胃癌细胞中并不是通过热点突变导致持续活化而致癌,而可能是通过ERas基因表达量的调节或形成新的剪接型KrasAE2而致癌。另外,Kras基因是一被受国际关注的肿瘤基因,新剪接型的发现可能会对Kras基因致癌机制产生新的认识,意义重大。     

Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer

IRX1 is originally characterized as a tumor suppressor gene of gastric cancer (GC) by our group based on serially original studies. However, the molecular regulatory mechanisms of IRX1 are not clear yet. Here, we identified protein arginine methyltransferase 5 (PRMT5) as a major upstream regulator of IRX1 for determining GC progression. Expression of PRMT5 was significantly increased in human GC tissues (433 out of 602 cases, 71.93%) compared with normal gastric mucosa, and exhibited diagnostic and prognostic potential. Overexpression of PRMT5 promoted tumorigenicity and metastasis of GC cells, while knockdown of PRMT5 abrogated tumorigenicity and metastasis of GC cells in vitro and in vivo. By co-immunoprecipitation and chromatin immunoprecipitation assays, we proved that PRMT5 elevated methylation levels of tumor suppressor IRX1 promoter via recruiting DNMT3A at promoter region. Knockdown of PRMT5 in SGC7901 and NCI-N87 cells decreased the recruitment of DNMT3A at IRX1 promoter, and reduced the methylation level of IRX1 promoter, then re-activated IRX1 expression. Whereas, overexpression of PRMT5 could epigenetically suppress IRX1 expression. Overall, PRMT5 promoted tumorigenicity and metastasis of gastric cancer cells via epigenetic silencing of IRX1. Targeting PRMT5 in GC might inhibit the malignant characters of GC and drawing a novel therapeutic potential.     

Epigenetic Silencing of miR-338-3p Contributes to Tumorigenicity in Gastric Cancer by Targeting SSX2IP

MicroRNA has been recently recognized as playing a prominent role in tumorigenesis and metastasis. Here, we report that miR-338-3p was epigenetically silenced in gastric cancer, and its down-regulation was significantly correlated with gastric cancer clinicopathological features. Strikingly, restoring miR-338-3p expression in SGC-7901 gastric cancer cells inhibited proliferation, migration, invasion and tumorigenicity in vitro and in vivo, at least partly through inducing apoptosis. Furthermore, we demonstrate the oncogene SSX2IP is a target of miR-338-3p. We propose that miR-338-3p functions as a tumor suppressor in gastric cancer, and the methylation status of its CpG island could serve as a potential diagnostic marker for gastric cancer.     

Upregulation of periostin prevents P53-mediated apoptosis in SGC-7901 gastric cancer cells

Periostin is frequently upregulated in human cancers including gastric cancer and implicated in cancer cell proliferation, invasion, and epithelial–mesenchymal transition. This study was undertaken to investigate the effects of periostin overexpression on the chemosensitivity of gastric cancer cells. We constructed a stable cell line overexpressing periostin in SGC-7901 human gastric cancer cells. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay revealed that periostin had no influence on the proliferation of SGC-7901 cells. Compared to empty vector-transfected cells, overexpression of periostin rendered SGC-7901 cells more resistant to cisplatin or 5-fluorouracil (5-FU)-induced apoptosis, accompanying with less release of cytochrome c from mitochondria and diminished cleavage of caspase-3 and poly (ADP-ribose) polymerase. Periostin-overexpressing cells treated with cisplatin or 5-FU showed significantly (p < 0.05) decreased expression of Bax and p53 proteins and increased expression of Bcl-2 protein, when compared to drug-treated mock counterparts. Restoration of p53 expression by delivering wild-type p53 gene resulted in a marked increase in drug-induced apoptosis in periostin-overexpressing SGC-7901 cells. Periostin overexpression elevated the phosphorylation of Akt. Pretreatment of periostin-overexpressing cells with an Akt inhibitor, MK-2206, partially rescued periostin-mediated inhibition of p53 expression and drug resistance. Taken together, our data indicate that periostin confers protection against cisplatin or 5-FU-induced apoptosis in SGC-7901 cells, likely through modulating the Akt/p53 pathway, and thus represents a potential therapeutic target in gastric cancer.